Reading NTHI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NTHI free→Reading NTHI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NTHI free→NASDAQHealth CareBiotechnologySnapshot 2026-06-12
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral, and the company was unprofitable over the past year, so its earnings quality can't be assessed. Risk is high, and the sector backdrop is a headwind, with NTHI compared to sector peers being below typical. If NTHI cuts guidance on the next call, that could have a meaningful negative impact, as the Street tends to walk down estimates. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $4.75. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Not enough peers to compare yet.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.43x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, the broad stock market, real (inflation-adjusted) rates, Fed net liquidity.
Not enough signal yet.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.24 → $-0.17 (+30.5% / 30d). 1 raised, 0 cut, 3 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 100% of analysts rate Buy.
2 PT revisions / 30d. Avg target 200.3% above current price.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$318.
How much price usually moves either way.
On a bad day, this stock has moved -$1,161.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $6,642.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for NTHI yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Entry into a M aterial Definitive Agreement. On June 10, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell up to an aggregate of $5,000,000 of its Series A Convertible Preferred Stock (the “Series A Preferred Stock”) in a private placement. The Series A Preferred Stock will be issued at a purchase price of $83…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
NTHI Neonc Technologies Holdings Inc | Below typical Show detailsSector percentile: 0 of 100 | — | high |
ABBV AbbVie | Above typical Show detailsSector percentile: 79 of 100 | full | low |
AMGN Amgen | Above typical Show detailsSector percentile: 75 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 96 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 82 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-12.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on reducing cash operating expenses to approximately $10.1 million for the year.
Newly stated in 2026-Q1. The company aims to reduce cash operating expenses to $10.1 million annually. However, cash from operating activities was negative at -$6.99 million in 2026-Q1, indicating limited progress towards this target so far.
“resulting in normalized ongoing cash operating expenses of approximately $10.1 million for the year.”
Amend the Certificate of Incorporation to authorize Series A Preferred Stock with specific preferences and rights.
Newly stated in 2026-Q1. The company amended its Certificate of Incorporation to authorize Series A Preferred Stock, setting the stage for future capital allocation strategies. The financial impact of this amendment is not yet reflected in the current financials.
“amended its Certificate of Incorporation... authorized the Series A Preferred Stock with such preferences and rights.”
The issuances of the shares of Series A Preferred Stock were not registered under the Securities Act of 1933, as amended (the “Securities Act”), but qualified for an exemption under Section 4(a)(2) of the Securities Act and by Rule 506 of Regulation D promulgated thereunder as transactions by an issuer not involving a public offering.
On June 10, 2026, the Company amended its Certificate of Incorporation by filing the Certificate of Designations, Preferences and Rights of the Series A Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware, which authorized the Series A Preferred Stock with such preferences and rights as set forth in the Certificate of Designation. General . The Company’s board of directors has designated six thousand (6,000) shares as the Series A Preferred…